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BIOTECHNOLOGY: EUROPE'S NEWEST NATURAL RESOURCE 
World shortages of raw materialsw the unrelenting search for new sources of energy 
and the unreliability of traditional sources of raw materials in the Third World 
are convincing science policy makers to fund more research in biotechnology. 
The European Commission has tackled the difficult question of how to overcome 
national and institutional reticence and to pour more money into the Community 
ef;tort in biotechnology~ In January of this year, the European Commission presented 
the results of their deliberations to the Council of Ministers -= a proposed 
programme of research (1) for the next five years, costing 23.5 million EUA (about 
£16 million)® The cost of the programme would be met by an equal sum from the 
participating countries, so that the research programme would in reality cost 
£32 millione This sum, spread over nine countries~ is small compared to what firms 
such as Cetus are spending on research and development, so the expert group had 
some difficulty selecting priorities for the programmeo 
New products, new processes 
Conservationists have joined Wbig business' pundits to pro.claim that the impact 
of biotechnology will be greater than the microchip" These enthusiasts believe that 
more research in biotechnology - the industrial processing of materials by 
biological agents such as micro-organisms - will yield newi non-polluting sources 
of industrial chemicals, organic fertilisers1i' and drugs, which will conserve our 
dwindling oil reserves$ New processes for mining metals, producing ethanol for 
fuel and for domestic waste disposal could win important export contracts for the 
country that forges a.head in biotechnology. Even government planners, notoriously 
conservative, a.re being wooed by the dream that these new processes ma.y take up 
the employment slack left by the gradual tran.sfer of heavy industries such as steel 
manufacturing to the Third Worldo 
.. Private industry in Ja.pan and the United States have already invested heavily in 
\;· biotechnology111 Unfortunately, with the exception of West Germany, most of the 
EEC countries lag far behind,, France and :Britain included@ There are big profits 
to be made; Japan's industrial activity in biotechnology stretches back over 40 years 
and earns over £5 billion each yea.re This figure represents over five per cent of 
the count.ey's Gross National Product(!) In the United States, scientists banded 
together during the last decade to form entrepreneurial commercial enterprises such 
aB Cetus and Genentech to bettar exploit their re~aarch in biotechnologve With 
their entry into the race, it is time for European scientists to reassesf the 
commercial importance of their research and to collaborate more effectively to combat 
competition from abroad before it is too late~ 
There is alre~ a long list of success~~ using micro-organisms, plant and animal 
cells, which grow quickly in vast :f'e~ntersID to manufacture antibiotics and 
vaccines, novel foods and animal feedstuffso Bu.t these successes were achieved, 
until very recently, by technical advances in traditional fermentation methods 
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which date back thousands of years to when man first brewed beer from cereals. 
Now genetic engineering has ushered in a revolutionary phase in biotechnologye 
Within the next decade, experts in genetiqs, biomolecular engineering and 
microbiology will be able to persuade a micro-organism to integrate genetic 
material (or DNA) foreign to its own into the structure of its cellQ Spliced 
into the bacterial DNA, the 'fo:reigner' will instruct the bacterial cell to 
manufacture 'foreign' proteins. This has alreac\Y been achieved in the laboratory. 
Scientists at Biogen - the European-based biotechnology firm - claim to have 
engineered a bug which will make the human protein interferon, which attacks 
disease-causing viruses, and could be a. cure for certain types of cancer. The 
trick will be to scale up the growth of the fast-growing host cells from the nall 
fermenters in the laboratories to the massive vats in commercial plants. 
The difficulty faced by all science policy makers faced with allocating small 
sums to biotechnology research is whether to support projects which will 
yield products of known commercial value, such ~ the widely-used industrial 
chemical ethanol, or to tackle the more complex human proteins such as insulin 
or interferon. Human proteins mq be more scientifically interesting yet ma., 
take 10-15 years to become commercially economic. Even then, the market will 
be small and safety regulations ma., prove a large stumbling block to industrial 
production in the factorym 
Stimulating research 
The aim of the European Commission's programme is to stimulate biotechnology 
research alrea<%r going on within the Community which is suitable for commercial 
exploitation. So the six 'projects' outlined in the proposal relate to two 
industrial themes. The first deals with the development of processes based 
on not one but two or more enzymes operating at different stages. Enzymes 
catalyse biological reactions and a problem industrial engineers have alw~s 
faced is that enzymes are difficult to control and are used up in these 
reactions, making them unsuitable for continuous commercial manufacture. If 
these enzymes can be immobilised in such a w,q so as to continue working in 
complex systems for as long as several :,ears, then such 1bioreactors' will 
yield much more elaborate products 'important 'to Eu.ropean industries'. 
The second theme revo1ves around using genetic engineering to alter micro-organisms 
of 'importance to European industries'. This involves a lot of basic research 
into the 1flV' genes are transferred from a foreign source into bacteria such 
u Escherichia coli and even the development of new hosts. 
Safety stu93 
Aware of the safety implications of growing engineered bugs in large numbers 
in the open conditions of a factor,-, the Commission's expert group allocates 
one project to stut\Ying the likelihood that t'hese bugs will mutate to more 
dangerous forms and to improving detection of dangerous contaminants. :rn 
preparing the programme, the Commission's experts relied on three studies (1) 
which examined work alrea.d;r in progr®sa within the Community. 
Should the Council of Ministers approve the programme, each participating country 
will send tw representatives to a comi ttee which will not only coordinate 
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the programme, but will also decide which of the many projects, alrea.t\Y 
rolling in, will receive funding.., However, biotechnology is moving ahead 
so rapidly that in five years time new priorities will have to be set., A 
subcommittee of FAST - the EEC 1s research programme for forecasting and 
assessment in science a.nd technology - is a.lread;y at work planning a long 
term strategy. The Commission has set aside over 520 OOO EUA (about £317 OOO) 
for the five year programme; again the participating institutions will 
contribute an equal a.mount. The projects range widely, looking not only 
at the options for scientific research within the Community but also at 
the wider' issues of manpower and training, the social acceptability of 
biotechnology, the implications for the Third World and the impact on the 
environment o 
